These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 36510639)

  • 1. Intraoperative detection of IDH-mutant glioma using fluorescence lifetime imaging.
    Noble Anbunesan S; Alfonso-Garcia A; Zhou X; Bec J; Lee HS; Jin LW; Bloch O; Marcu L
    J Biophotonics; 2023 Apr; 16(4):e202200291. PubMed ID: 36510639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.
    Park YW; Kim S; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Kim SH; Lee SK; Chang JH
    Eur Radiol; 2024 Feb; 34(2):1376-1387. PubMed ID: 37608093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI features predict tumor grade in isocitrate dehydrogenase (IDH)-mutant astrocytoma and oligodendroglioma.
    Joyner DA; Garrett J; Batchala PP; Rama B; Ravicz JR; Patrie JT; Lopes MB; Fadul CE; Schiff D; Jain R; Patel SH
    Neuroradiology; 2023 Jan; 65(1):121-129. PubMed ID: 35953567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Performance of [
    Nakajo K; Uda T; Kawashima T; Terakawa Y; Ishibashi K; Tsuyuguchi N; Tanoue Y; Nagahama A; Uda H; Koh S; Sasaki T; Ohata K; Kanemura Y; Goto T
    World Neurosurg; 2021 Apr; 148():e471-e481. PubMed ID: 33444827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Clinical, Tumor, and Treatment Characteristics With Seizure Control in Patients With
    Bruno F; Pellerino A; Conti Nibali M; Pronello E; Cofano F; Rossi M; Levis M; Bertero L; Soffietti R; Cassoni P; Garbossa D; Bello L; Rudà R
    Neurology; 2024 May; 102(10):e209352. PubMed ID: 38684041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.
    Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA
    J Neurosurg; 2020 Jan; 132(1):180-187. PubMed ID: 30611146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rare dual-genotype IDH mutant glioma: Review of previously reported cases and two new cases of true "oligoastrocytoma".
    Sutherland I; DeWitt J; Thomas A
    Neuropathology; 2024 Oct; 44(5):401-407. PubMed ID: 38581197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
    Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T
    Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorescence-guidance in non-Gadolinium enhancing, but FET-PET positive gliomas.
    Schebesch KM; Brawanski A; Doenitz C; Rosengarth K; Proescholdt M; Riemenschneider MJ; Grosse J; Hellwig D; Höhne J
    Clin Neurol Neurosurg; 2018 Sep; 172():177-182. PubMed ID: 30032095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating IDH-mutant astrocytomas and 1p19q-codeleted oligodendrogliomas using DSC-PWI: high performance through cerebral blood volume and percentage of signal recovery percentiles.
    Pons-Escoda A; Garcia-Ruiz A; Naval-Baudin P; Martinez-Zalacain I; Castell J; Camins A; Vidal N; Bruna J; Cos M; Perez-Lopez R; Oleaga L; Warnert E; Smits M; Majos C
    Eur Radiol; 2024 Aug; 34(8):5320-5330. PubMed ID: 38282078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seizures in patients with IDH-mutated lower grade gliomas.
    Carstam L; Rydén I; Jakola AS
    J Neurooncol; 2022 Nov; 160(2):403-411. PubMed ID: 36258151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system.
    Nam YK; Park JE; Park SY; Lee M; Kim M; Nam SJ; Kim HS
    Eur Radiol; 2021 Oct; 31(10):7374-7385. PubMed ID: 34374800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of diagnostic performance of radiologist- and AI-based assessments of T2-FLAIR mismatch sign and quantitative assessment using synthetic MRI in the differential diagnosis between astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted.
    Kikuchi K; Togao O; Yamashita K; Momosaka D; Kikuchi Y; Kuga D; Yuhei S; Fujioka Y; Narutomi F; Obara M; Yoshimoto K; Ishigami K
    Neuroradiology; 2024 Mar; 66(3):333-341. PubMed ID: 38224343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T2-FLAIR Mismatch: An Imaging Biomarker for Children's
    van Maren EA; Dankbaar JW; Wesseling P; Plasschaert S; Muhlebner A; Hoving EW; Robe PA; Snijders TJ; Hoogendijk R; Kranendonk MEG; Lequin MH
    AJNR Am J Neuroradiol; 2024 Jun; 45(6):747-752. PubMed ID: 38724203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor.
    Zhao B; Xia Y; Yang F; Wang Y; Wang Y; Wang Y; Dai C; Wang Y; Ma W
    Mol Med; 2022 Mar; 28(1):34. PubMed ID: 35287567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the Prognostic Role of Age, Extent of Resection, and Tumor Grade between Astrocytoma IDHmt and Oligodendroglioma: A Single-Center Cohort Study.
    van der Vaart T; Wijnenga MMJ; van Garderen K; Dubbink HJ; French PJ; Smits M; Dirven CMF; Kros JM; Vincent AJPE; van den Bent MJ
    Clin Cancer Res; 2024 Sep; 30(17):3837-3844. PubMed ID: 38990096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microvascular characteristics of lower-grade diffuse gliomas: investigating vessel size imaging for differentiating grades and subtypes.
    Guo H; Kang H; Tong H; Du X; Liu H; Tan Y; Yang Y; Wang S; Zhang W
    Eur Radiol; 2019 Apr; 29(4):1893-1902. PubMed ID: 30276676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in
    Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH
    AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma].
    Pan Y; Qi XL; Wang LM; Dong RF; Zhang M; Zheng DF; Chang Q; Zhong YF
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):292-8. PubMed ID: 24004584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.